Comparison of Neutropenia Associated with Ceftaroline or Ceftriaxone in Patients Receiving at Least 7 Days of Therapy for Severe Infections.
Veve MP, Stuart M, and Davis SL. Comparison of Neutropenia Associated with Ceftaroline or Ceftriaxone in Patients Receiving at Least 7 Days of Therapy for Severe Infections. Pharmacotherapy 2019; 39(8):809-815.
STUDY OBJECTIVE: Ceftarolinefosamil is a cephalosporin with broad clinical utility; however, limited data suggest that prolonged ceftaroline exposure may be associated with neutropenia. The objective was to determine drug and patient factors associated with neutropenia in patients receiving ceftaroline or ceftriaxone for deep-seated infections.
DESIGN: Retrospective, ratio-matched cohort study.
SETTING: Four acute-care hospitals within an urban health care system.
PATIENTS: A total of 176 hospitalized adults who received definitive ceftaroline (44 patients) or ceftriaxone (132 patients) therapy for at least 7 days between January 2013 and April 2017 for any of the following indications: bone and joint infections (BJI), infective endocarditis (IE), or bloodstream infections (BSI).
MEASUREMENTS AND MAIN RESULTS: The primary outcome was development of neutropenia while receiving cephalosporin therapy, defined as an absolute neutrophil count (ANC)/mm
CONCLUSION: Prolonged ceftaroline use was an independent risk factor for developing mild neutropenia. Clinicians should be cognizant of ANC monitoring in scenarios where prolonged ceftaroline courses are prescribed.